Martin Connor
@connorurol.bsky.social
NIHR Clinical Lecturer in Urology | Imperial College London | Prostate Cancer | Urology Oncology Trials -> #AVIDITY #ATLANTA #LASERComplete #CAVALThromb | imperial.ac.uk/people/m.connor
Reposted by Martin Connor
📢 Join us at @IP_London
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
Description
Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...
www.imperial.ac.uk
April 2, 2025 at 11:29 AM
📢 Join us at @IP_London
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
Thank you to @thetimes.com 📰for covering my first major grant success
- the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social
www.thetimes.com/uk/healthcar...
- the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social
www.thetimes.com/uk/healthcar...
‘Groundbreaking’ scan for men with prostate cancer could save lives
Researchers hope the technology will help to create personalised treatment plans to prevent the disease becoming terminal
www.thetimes.com
March 12, 2025 at 2:27 PM
Thank you to @thetimes.com 📰for covering my first major grant success
- the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social
www.thetimes.com/uk/healthcar...
- the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social
www.thetimes.com/uk/healthcar...
Great presentation from our PhD fellow Archana 👏🥇 at the RSM London showing the possibilities of immediate bladder pathology at time of TURBT using the Histolog FCM scanner! @archanagk.bsky.social @ip-london.bsky.social #RSMUrology #LaserComplete #TheUrologyFoundation
December 6, 2024 at 8:54 PM
Great presentation from our PhD fellow Archana 👏🥇 at the RSM London showing the possibilities of immediate bladder pathology at time of TURBT using the Histolog FCM scanner! @archanagk.bsky.social @ip-london.bsky.social #RSMUrology #LaserComplete #TheUrologyFoundation
Reposted by Martin Connor
Working link to full open access article here: www.bmj.com/content/387/...
November 23, 2024 at 2:09 PM
Working link to full open access article here: www.bmj.com/content/387/...
Reposted by Martin Connor
ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
November 23, 2024 at 3:04 AM
ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
Reposted by Martin Connor
It was a record meeting for Imperial Prostate at #BAUSOncology 2024 with presentations on prostate cancer screening, early detection, molecular imaging and discussion of many of our ongoing/upcoming trials from our fellows, lecturers, and consultants #ATLAS #AVIDITY #FLUORESCE #PACIFIC #TRANSFORM
November 15, 2024 at 10:05 PM
It was a record meeting for Imperial Prostate at #BAUSOncology 2024 with presentations on prostate cancer screening, early detection, molecular imaging and discussion of many of our ongoing/upcoming trials from our fellows, lecturers, and consultants #ATLAS #AVIDITY #FLUORESCE #PACIFIC #TRANSFORM